IRIDEX to Present at the 2020 Stifel Virtual Healthcare Conference
IRIDEX Corporation (Nasdaq: IRIX) announced its participation in the Stifel Virtual Healthcare Conference on November 17, 2020, at 4:40 pm ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IRIDEX Corporation (Nasdaq: IRIX) announced its participation in the Stifel Virtual Healthcare Conference on November 17, 2020, at 4:40 pm ET. David I. Bruce, the CEO, will present, and interested individuals can access the live and archived webcast via the IRIDEX website.
IRIDEX specializes in laser-based medical systems for ophthalmology, notably using MicroPulse technology for treating conditions like glaucoma and diabetic macular edema. Its products are available in over 100 countries.
Details
News Market Reaction – IRIX
The recorded move for IRIX in the trading session of this news was -0.28%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to participate in the upcoming Stifel Virtual Healthcare Conference.
David I. Bruce, IRIDEX’s President and Chief Executive Officer, is scheduled to present on Tuesday, November 17, 2020, at 4:40 pm ET. Interested parties may access a live and archived webcast of the presentation at http://www.iridex.com.
About IRIDEX
IRIDEX Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. IRIDEX’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the IRIDEX website at www.iridex.com.
Investor Relations Contact
Leigh Salvo
(415) 937-5404
investors@iridex.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.